Bob Steininger is senior vice president, CMC at Surface Oncology, bringing over three decades of manufacturing experience to the team. Previously, he advised Voyager on production for their single-use adeno-associated virus (AAV) gene therapy portfolio, was senior vice president of manufacturing at Acceleron, and vice president of process sciences at Millennium Pharmaceuticals (now Takeda). Additionally, Bob held positions of increasing responsibility over 17 years at Genetics Institute (now Pfizer) in clinical production, process technology, and genomics research. Bob is a founding member of the Mass Biomanufacturing Roundtable of the Mass Biotech Council, chairman of the ASTM Subcommittee on Biotechnology Standards, and has been a member of the advisory board of Chemical Engineering and Engineering Department of the University of Massachusetts, Amherst. He received a bachelor’s degree in chemistry from the Massachusetts Institute of Technology and a master’s degree in chemical engineering from the University of California, Berkeley.